"The pharmacist remains a very important member of the healthcare team that has the ability to explain to the patient the differences between the biologic and the biosimilar. It is the pharmacist–patient relationship that will assist the patient in making the best decisions to obtain the optimal clinical outcome," said Larry D. Wagenknecht, PharmD, FMPA, FAPhA, CEO of the Michigan Pharmacists Association.
Recently, Michigan Governor, Republican Rick Snyder, signed into effect legislation that creates a pathway for the substitution of FDA-designated interchangeable biosimilars for their reference products at the pharmacy level. The Center for Biosimilars® interviewed Larry D. Wagenknecht, PharmD, FMPA, FAPhA, CEO of the Michigan Pharmacists Association on his organization’s stance on the new law.
When asked if his organization supported the bill, Wagenknecht said in an email, “The Michigan Pharmacists Association did end up supporting the legislation after some changes were made to the prescriber notification section of the bill.” He added that the Association wants to ensure that the law does not create any undue barriers in providing patients with access to the best options that will treat their conditions.
Currently, there are no FDA-approved interchangeable biosimilars, nor has any drug maker sought such a designation for a biosimilar product. With respect to the rationale for passing legislation dealing with interchangeable biosimilars now, Wagenknecht said the move was in preparation for the future: “The benefit of passing the bill now [March 2018] is minimal since the opportunity for substitution of a biosimilar really isn’t an option today. However, with the medications in the biosimilar pipeline, there will likely be opportunities in the coming years."
It remains unclear whether legislation passed concerning the substitution of interchangeable biosimilars, which has been passed or considered in numerous other states, such as South Dakota and Wisconsin in the early months of this year, will have any impact on uptake amongst prescribers of biosimilar medicines.
Wagenknecht said, “[The prescribing of biosimilars] is very difficult to predict. Biosimilar medications tend to treat more complicated medical conditions, so having a law on the books is not going to increase the use of biosimilar medications. The economics of healthcare will push for the use of biosimilars once they are available.”
Asked if members of his organization dispense biosimilars now, Wagenknecht said, “Our members do dispense biologics, and since the opportunity of dispensing biosimilars is not prevalent, we really don’t know how patients are going to respond. The pharmacist remains a very important member of the healthcare team that has the ability to explain to the patient the differences between the biologic and the biosimilar. It is the pharmacist—patient relationship that will assist the patient in making the best decisions to obtain the optimal clinical outcome.”
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.